6-(3-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one | 858946-44-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(3-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 6-(3-Hydroxyphenyl)-3,4-dihydronaphthalene-1(2H)-one；6-(3-hydroxyphenyl)-3,4-dihydro-2H-naphthalen-1-one
• CAS: 858946-44-8
• 化学式: C₁₆H₁₄O₂
• 分子量: 238.286
• InChiKey: AGJHSJLDWGVYAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(3-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one 在 palladium on activated charcoal 4-异丙基甲苯 作用下， 反应 6.0h， 生成 6-(3-hydroxyphenyl)-1-naphthol
  参考文献：
  名称：

  （羟苯基）萘和喹啉衍生物的设计，合成和生物学评估：用于治疗雌激素依赖性疾病的17β-羟类固醇脱氢酶1型（17β-HSD1）的有效和选择性非甾体抑制剂。

  摘要：

  人类17β-羟基类固醇脱氢酶1（17beta-HSD1）催化将弱雌激素雌酮（E1）还原为强效雌二醇（E2）。该反应在靶细胞中发生，在靶细胞中通过雌激素受体（ER）发挥雌激素作用。已知雌激素，尤其是E2会刺激激素依赖性疾病的扩散。17beta-HSD1在许多乳腺肿瘤中过表达。因此，它是治疗这些疾病的有吸引力的靶标。基于配体和结构的药物设计导致发现17beta-HSD1的新型，选择性和有效抑制剂。合成了苯基取代的双环部分，作为类固醇底物的模拟物。使用计算方法来了解它们与蛋白质的相互作用。

  DOI：

  10.1021/jm701447v
• 作为产物：
  描述：

  6-羟基-1-四氢萘酮 在 吡啶 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 6-(3-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  ERβ Ligands. 3. Exploiting Two Binding Orientations of the 2-Phenylnaphthalene Scaffold To Achieve ERβ Selectivity

  摘要：

  The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERbeta were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERbeta, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

  DOI：

  10.1021/jm058173s

文献信息

• 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
  申请人：Hartmann Rolf

  公开号：US20100204234A1

  公开（公告）日：2010-08-12

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂以及生产方法。
• Synthesis and Biological Evaluation of Spiro-δ-lactones as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 2 (17β-HSD2)
  作者：Kuiying Xu、Marie Wetzel、Rolf W. Hartmann、Sandrine Marchais-Oberwinkler

  DOI：10.2174/157018011795514230

  日期：2011.6.1

  17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyzes the oxidation of the potent estradiol (E2) to the less active estrogen estrone (E1). Inhibitors of this enzyme should maintain the local level of E2 in bone tissue when the E2 concentration in the circulation drops and therefore might be useful for the treatment of osteoporosis. In this work, novel non-steroidal spiro-δ-lactone compounds

  17β-羟基类固醇脱氢酶2（17β-HSD2）催化强效雌二醇（E2）氧化为活性较低的雌激素雌酮（E1）。当循环中的E2浓度下降时，该酶的抑制剂应维持骨组织中E2的局部水平，因此可能对治疗骨质疏松症有用。在这项工作中，合成了设计为17β-HSD2抑制剂的新型非甾体螺-δ-内酯化合物，并研究了它们的理化和生物学特性。这些新的螺-δ-内酯对于进一步开发而言不够稳定，并且对酶的抑制作用很低。
• 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases
  申请人：Hartmann Rolf

  公开号：US08546392B2

  公开（公告）日：2013-10-01

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂及其生产方法。
• COMPOUND
  申请人：VICKER Nigel

  公开号：US20090186900A1

  公开（公告）日：2009-07-23

  There is provided a compound of Formula I wherein the various symbols are as defined in the description, and a method of manufacturing a medicament for use in the therapy of a condition or disease associated with 17β-hydroxysteroid dehydrogenase (17β-HSD), comprising a compound of Formula I.

  提供了一种式子为I的化合物，其中各符号的定义如说明书所述，并提供一种制造药物的方法，用于治疗与17β-羟基类固醇脱氢酶（17β-HSD）相关的疾病或病症，包括化合物I。
• WO2007/96647
  申请人：——

  公开号：——

  公开（公告）日：——